We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIAGAST

DIAGAST develops, manufactures and markets reagents and automated systems for blood group determination. Its wide pro... read more Featured Products: More products

Download Mobile App





Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)

DIAGAST (Loos, France) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it presented its latest immunohaematology solutions and also organized a scientific workshop for Blood Transfusion Day.

Blood transfusion is at the heart of healthcare professionals’ concerns. From the donor to the patient, there are many challenges to be met to ensure the compatibility of transfusions. DIAGAST is a worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. The company develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST offers high performance product ranges and automated systems, guaranteeing the quality of transfusion diagnosis and patient safety.

At MEDLAB Middle East 2022, DIAGAST showcased its QWALYS 3 EVO automated system which is the only fully-automated system on the market using the magnetization of erythrocytes, a process that no longer requires washing and centrifugation steps. DIAGAST’s Erythrocyte Magnetized (EM) technology is based on Red Blood Cells (RBC) magnetization. This innovative solution enables avoiding washing and centrifugation steps usually associated to traditional immunohaematology testing. It uses a patented high-density solution (NanoLys) which creates a barrier that blocks non-specific antibodies which could interfere when performing direct and indirect antiglobulin tests. A latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centers and hospitals.

Related Links:
DIAGAST 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.